Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

“Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma– A real life study”
  • +23
  • Blanca Barroso,
  • Marcela Valverde,
  • Isam Alobid,
  • Olaguibel JM,
  • Manuel Rial Prado,
  • Santiago Quirce,
  • Ebymar Arismendi,
  • Pilar Barranco,
  • Diana Betancor,
  • IRINA BOBOLEA,
  • Blanca Cárdaba,
  • Maria-Jesús Cruz,
  • Elena Curto,
  • Javier Domínguez-Ortega,
  • Francisco-Javier González-Barcala,
  • Carlos Martinez Rivera,
  • Ignacio Mahillo,
  • Xavier Muñoz,
  • César Picado,
  • Vicente Plaza,
  • Jose Rodrigo-Muñoz,
  • Lorena Soto Retes,
  • Antonio Valero,
  • VICTORIA DEL POZO,
  • Joaquim Mullol,
  • Joaquin Sastre
Blanca Barroso
Hospital Universitario Fundacion Jimenez Diaz

Corresponding Author:[email protected]

Author Profile
Marcela Valverde
Hospital Universitario Fundacion Jimenez Diaz
Author Profile
Isam Alobid
Centro de Investigacion Biomedica en Red
Author Profile
Olaguibel JM
Centro de Investigacion Biomedica en Red
Author Profile
Manuel Rial Prado
Centro de Investigacion Biomedica en Red
Author Profile
Santiago Quirce
Centro de Investigacion Biomedica en Red
Author Profile
Ebymar Arismendi
Centro de Investigacion Biomedica en Red
Author Profile
Pilar Barranco
Centro de Investigacion Biomedica en Red
Author Profile
Diana Betancor
Hospital Universitario Fundacion Jimenez Diaz
Author Profile
IRINA BOBOLEA
Centro de Investigacion Biomedica en Red
Author Profile
Blanca Cárdaba
Centro de Investigacion Biomedica en Red
Author Profile
Maria-Jesús Cruz
Centro de Investigacion Biomedica en Red
Author Profile
Elena Curto
Centro de Investigacion Biomedica en Red
Author Profile
Javier Domínguez-Ortega
Centro de Investigacion Biomedica en Red
Author Profile
Francisco-Javier González-Barcala
Centro de Investigacion Biomedica en Red
Author Profile
Carlos Martinez Rivera
Centro de Investigacion Biomedica en Red
Author Profile
Ignacio Mahillo
Hospital Universitario Fundacion Jimenez Diaz
Author Profile
Xavier Muñoz
Centro de Investigacion Biomedica en Red
Author Profile
César Picado
Centro de Investigacion Biomedica en Red
Author Profile
Vicente Plaza
Centro de Investigacion Biomedica en Red
Author Profile
Jose Rodrigo-Muñoz
Centro de Investigacion Biomedica en Red
Author Profile
Lorena Soto Retes
Centro de Investigacion Biomedica en Red
Author Profile
Antonio Valero
Centro de Investigacion Biomedica en Red
Author Profile
VICTORIA DEL POZO
Centro de Investigacion Biomedica en Red
Author Profile
Joaquim Mullol
Centro de Investigacion Biomedica en Red
Author Profile
Joaquin Sastre
Hospital Universitario Fundacion Jimenez Diaz
Author Profile

Abstract

Background. Chronic rhinosinusitis with nasal polyps (CRSwNP), characterized by partial (hyposmia) or total (anosmia) loss of smell, is commonly associated with asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD), worsens disease severity and quality of life. The objective of this study was to determine whether, in real-life conditions, biological treatments prescribed for severe asthma can improve olfaction in patients with CRSwNP. A further objective was to compare smell improvement in N-ERD and non-N-ERD subgroups. Methods. A multicenter, non-interventional, retrospective, observational study was performed, including 206 patients with severe asthma undergoing biological treatment (omalizumab, mepolizumab, benralizumab, or reslizumab) with CRSwNP. Results. Improved olfaction was found after treatment with all monoclonal antibodies: omalizumab (35.8%), mepolizumab (35.4%), reslizumab (35.7%), and benralizumab (39.1%), with no differences between groups. Patients with atopy, greater use of short course systemic corticosteroids, and larger polyp size were more likely to experience improvement in smell. The proportion of patients experiencing smell improvement was similar between the N-ERD (37%) and non-N-ERD (35.7%) groups. Conclusions. This is the first study to compare real-life improvement in sense of smell among patients undergoing long-term treatment with omalizumab, mepolizumab, reslizumab, or benralizumab for severe asthma and associated CRSwNP. Approximately 4 out of 10 patients reported a subjective improvement in sense of smell (with non-significant differences between biologic drugs). No differences were found in smell improvement between the N-ERD and non-N-ERD group.
13 Apr 2022Published in Journal of Investigational Allergy and Clinical Immunology volume 33 issue 1. 10.18176/jiaci.0812